Moyamoya Disease and Moyamoya Syndrome

R. Michael Scott, M.D., and Edward R. Smith, M.D.

From the Department of Neurosurgery, Children’s Hospital Boston, and Harvard Medical School, Boston. Address reprint requests to Dr. Smith at the Department of Neurosurgery, Children’s Hospital Boston, 300 Longwood Ave., Boston, MA 02115, or at edward.smith@childrens.harvard.edu.


The moyamoya syndrome is a cerebrovascular condition that predisposes affected patients to stroke in association with progressive stenosis of the intracranial internal carotid arteries and their proximal branches. Reduced blood flow in the major vessels of the anterior circulation of the brain leads to compensatory development of collateral vasculature by small vessels near the apex of the carotid, on the cortical surface, leptomeninges, and branches of the external carotid artery supplying the dura and the base of the skull. In rare cases, this process also involves the posterior circulation, including the basilar and posterior cerebral arteries.

First described in 1957 as “hypoplasia of the bilateral internal carotid arteries,”1 the characteristic appearance of the associated network of abnormally dilated collateral vessels on angiography was later likened to “something hazy, like a puff of cigarette smoke,”2 which, in Japanese, is moyamoya (Fig. 1). Although “spontaneous occlusion of the circle of Willis” has recently been suggested as an alternative to the more evocative name “moyamoya,” the International Classification of Diseases recognizes “moyamoya” as the specific name for this condition.3

Patients with the characteristic moyamoya vasculopathy who also have well-recognized associated risk factors (described below) are categorized as having the moyamoya syndrome, whereas patients with no known associated risk factors are said to have moyamoya disease. By definition, the pathognomonic arteriographic findings are bilateral in moyamoya disease, although the severity can differ between sides.2 Patients with unilateral findings have the moyamoya syndrome, even if they have no other associated risk factors.3 However, contralateral disease eventually develops in up to 40% of patients initially presenting with unilateral findings.4,5 When used alone, without the distinguishing modifier of “disease” or “syndrome,” “moyamoya” refers solely to the distinctive findings on cerebral arteriography, independently of the cause.

**Epidemiologic Features**

Originally considered to affect predominantly persons of Asian heritage, moyamoya has now been observed throughout the world in people of many ethnic backgrounds, including American and European populations.6,7 The incidence peaks in two age groups: children who are approximately 5 years of age and adults in their mid-40s.8-11 There are nearly twice as many female patients as male patients.8,9,12 Moyamoya is the most common pediatric cerebrovascular disease in Japan, with a prevalence of approximately 3 cases per 100,000 children.8,9,13 The incidence among all patients with moyamoya in Europe appears to be about 1/10th of that observed in Japan.14 Results from a 2005 American review suggest an incidence of 0.086 case per 100,000 persons.15 Reported incidence-rate ratios are 4.6 for Asian Americans, 2.2 for blacks, and 0.5 for Hispanics, as compared with whites.15
Symptoms and signs of moyamoya can be attributed to changes in flow resulting from stenosis of the internal carotid artery. Broadly speaking, there are two major etiologic categories of symptoms: those due to brain ischemia (i.e., stroke, transient ischemic attacks [TIAs], and seizures)
and those due to the deleterious consequences of the compensatory mechanisms responding to the ischemia (i.e., hemorrhage from fragile collateral vessels and headache from dilated transdural collaterals). Individual variations in the degree of arterial involvement, progression of stenosis, regions of ischemic cortex, and response to the reduction in blood supply help to explain the wide range of clinical presentations.

**AGE-RELATED AND GEOGRAPHIC DIFFERENCES IN PRESENTATION**

In the United States, the majority of affected adults and children present with ischemic symptoms, although the rate of hemorrhage among adults is approximately seven times as high as the rate among children (20.0% vs. 2.8%). Manifestations vary among geographic regions. Studies involving Asian populations indicate that adults have much higher rates of hemorrhage as a presenting symptom (42%) than adults in the United States. In contrast, only 2.8% of children in Asian populations present with hemorrhage, and 68% present with TIAs or ischemic strokes (Table 1). Children have a higher rate of completed strokes; it is thought that because of their immature verbal and reporting skills, they simply may not be able to communicate TIA symptoms clearly, delaying diagnosis and increasing the likelihood of a completed stroke.

**ISCHEMIC SYMPTOMS**

Symptoms of cerebral ischemia in moyamoya are typically associated with the regions of the brain supplied by the internal carotid arteries and middle cerebral arteries; these regions include the frontal, parietal, and temporal lobes. Hemiparesis, dysarthria, aphasia, and cognitive impairment are common. Patients may also have seizures, visual deficits, syncope, or personality changes that can be mistaken for psychiatric illness. Ischemic symptoms may be transient or fixed. A TIA or stroke may be precipitated by common childhood events such as hyperventilation with crying. Signs and symptoms of cerebral ischemia can result from exertion or even from induction of anesthesia for a minor surgical procedure. The presumed mechanism of these events is that normal cortical vessels, already maximally dilated in patients with chronic ischemia, constrict in response to the decrease in the partial pressure of carbon dioxide due to hyperventilation, resulting in reduced cerebral perfusion. Dehydration may also precipitate ischemic symptoms.

**HEMORRHAGE**

Intracranial hemorrhage is common in adults with moyamoya, but it has also been described in children. The location of the hemorrhage can be intraventricular, intraparenchymal (frequently in the region of the basal ganglia), or subarachnoid. Historically, bleeding has been attributed to rupture of fragile collateral vessels associated with moyamoya as progressive stenosis of the internal carotid artery occurs. Shifting circulatory patterns at the base of the brain have been impli-

<table>
<thead>
<tr>
<th>Variable</th>
<th>Prevalence*</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Symptoms at presentation</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Common</strong></td>
<td></td>
</tr>
<tr>
<td>Ischemic stroke</td>
<td>50–75</td>
</tr>
<tr>
<td>Transient ischemic attack (including drop attacks)</td>
<td>50–75</td>
</tr>
<tr>
<td>Hemorrhage (in adults)</td>
<td>10–40</td>
</tr>
<tr>
<td><strong>Less common</strong></td>
<td></td>
</tr>
<tr>
<td>Seizures</td>
<td></td>
</tr>
<tr>
<td>Headache</td>
<td></td>
</tr>
<tr>
<td><strong>Rare</strong></td>
<td></td>
</tr>
<tr>
<td>Choreiform movements</td>
<td></td>
</tr>
<tr>
<td>Cognitive or psychiatric changes</td>
<td></td>
</tr>
<tr>
<td><strong>Associated characteristics and conditions</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Common</strong></td>
<td>50–75</td>
</tr>
<tr>
<td>Angiographic findings of moyamoya without other disease</td>
<td></td>
</tr>
<tr>
<td>Asian heritage</td>
<td></td>
</tr>
<tr>
<td><strong>Less common (moyamoya syndrome)</strong></td>
<td>10–20</td>
</tr>
<tr>
<td>Sickle cell disease</td>
<td></td>
</tr>
<tr>
<td>Neurofibromatosis type 1</td>
<td></td>
</tr>
<tr>
<td>Cranial therapeutic irradiation</td>
<td></td>
</tr>
<tr>
<td>Down’s syndrome</td>
<td></td>
</tr>
<tr>
<td><strong>Rare (moyamoya syndrome)</strong></td>
<td>&lt;10</td>
</tr>
<tr>
<td>Congenital cardiac anomaly</td>
<td></td>
</tr>
<tr>
<td>Renal-artery stenosis</td>
<td></td>
</tr>
<tr>
<td>Giant cervicofacial hemangiomas</td>
<td></td>
</tr>
<tr>
<td>Hyperthyroidism</td>
<td></td>
</tr>
</tbody>
</table>

* The prevalence is among persons with diagnosed moyamoya disease or syndrome.
cated in the development of cerebral aneurysms (usually at the apex of the basilar artery and posterior communicating artery, areas of increased shear stress in moyamoya); this may be another cause of hemorrhage in moyamoya.24,25

HEADACHE AND OTHER SYMPTOMS

Headache is a frequent presenting symptom in patients with moyamoya. A review suggested that dilatation of meningeal and leptomeningeal collateral vessels may stimulate dural nociceptors.26 Typically, headache is migrainelike in quality and refractory to medical therapies; it persists in up to 63% of patients, even after successful surgical revascularization.20 In some patients, however, headache subsides within 1 year after surgical treatment of moyamoya, possibly reflecting the regression of basilar collateral vessels.

Dilated moyamoya-associated collateral vessels in the basal ganglia have also been implicated in the development of choreiform movements, another presentation of this condition in children.12,27 To our knowledge, there are no published series documenting the clinical course of this movement disorder in moyamoya, but in our series of children presenting with choreiform movements, 8 of 10 had resolution 1 year after revascularization surgery, a finding that was concomitant with reduction in moyamoya-associated collaterals in the basal ganglia.

An ophthalmologic finding occasionally seen in association with moyamoya is the “morning glory disk,” an enlargement of the optic disk with dilated perforating arteries that are believed to be a combination of preexisting and newly developed vessels.34,35 These collaterals show evidence of stress related to increased flow, including the combination of fragmented elastic lamina, thinned media in the vessel wall, and the presence of microaneurysms; these findings help to explain why some patients present with hemorrhage.36 Other moyamoya-related vessels are collapsed and their lumens thrombosed, findings that may account for the cause of ischemic symptoms.37

ASSOCIATED CONDITIONS

Moyamoya is strongly associated with radiotherapy to the head or neck (particularly radiotherapy for optic gliomas, craniopharyngiomas, and pituitary tumors), although the dose of radiation that is capable of causing this effect is unknown and the time between treatment and the onset of disease can range from months to decades. Down's syndrome, neurofibromatosis type 1 (with or without tumors of the hypothalamic–optic pathway), and sickle cell disease have also been reported in association with moyamoya.12,19,29,30 There are numerous reported links between moyamoya and a wide variety of other disorders (Table 1).12

PATHOPHYSIOLOGICAL FEATURES

Angiographic changes associated with moyamoya are shared by a diverse collection of genetic and acquired conditions. The heterogeneity of the pathophysiological processes underlying these radiographic findings reflects distinct clinical presentations and responses to therapeutic interventions. Three types of research have aimed at explaining the pathogenesis of moyamoya: pathological analysis of affected tissue, genetic-linkage studies, and studies of the role of angiogenesis and extracellular matrix–related peptides in disease development and progression.

ANALYSIS OF PATHOLOGICAL FINDINGS

In patients with moyamoya, stenosis occurs in the distal internal carotid artery and often involves the proximal anterior and middle cerebral arteries (Fig. 2A). Pathological analysis has revealed that affected vessels do not show arteriosclerotic or inflammatory changes leading to occlusion.31 Rather, vessel occlusion results from a combination of hyperplasia of smooth-muscle cells and luminal thrombosis (Fig. 2C through 2F). The media is often attenuated, with irregular elastic lamina.32 Caspase-dependent apoptosis has been implicated as a contributory mechanism in the associated degradation of the arterial wall.33

Moyamoya-associated collaterals are generally dilated perforating arteries that are believed to be a combination of preexisting and newly developed vessels.34,35 These collaterals show evidence of stress related to increased flow, including the combination of fragmented elastic lamina, thinned media in the vessel wall, and the presence of microaneurysms; these findings help to explain why some patients present with hemorrhage.36 Other moyamoya-related vessels are collapsed and their lumens thrombosed, findings that may account for the cause of ischemic symptoms.37

GENETIC STUDIES

Genetic factors appear to play a major role in moyamoya. The proportion of patients who have affected first-degree relatives is 10% in Japan, and a rate of 6% was reported in a U.S. series.12,31 Associations with loci on chromosomes 3, 6, 8, and 17, as well as specific HLA haplotypes, have been described.38-42 Most familial cases appear to be polygenic or inherited in an autosomal dominant fashion with
incomplete penetrance. A 2008 study reported a major gene locus for autosomal dominant moyamoya disease on chromosome 17q25; this finding requires replication. The recent discovery of a moyamoya-associated mutation in this region affecting TIMP-2 (tissue inhibitor of matrix metalloproteinase type 2) is of particular interest, given the important role of extracellular-matrix remodeling and angiogenesis in both the primary arteriopathy and subsequent response of the ischemic brain.\textsuperscript{35,44}

However, despite evidence of a genetic basis of moyamoya, important caveats remain. For example, reports of identical twins with only one affected sibling\textsuperscript{12,45} provide support for the premise that environmental factors precipitate the clinical emergence of the condition in susceptible persons.

**Angiogenesis and Extracellular-Matrix–Related Peptides**

Levels of many growth factors, enzymes, and other peptides have been reported to be increased in association with moyamoya, including basic fibroblast growth factor, transforming growth factor β-1, hepatocyte growth factor, vascular endothelial growth factor, matrix metalloproteinases, intracellular adhesion molecules, and hypoxia-inducing factor 1α.\textsuperscript{35,46-52} Levels of individual peptides have been studied in cultured smooth-muscle cells, dura, cerebrospinal fluid, and vessels. However, to our knowledge, no comprehensive investigations have surveyed groups of mechanistically related proteins. An example highlighting the potential usefulness of such a strategy may be relevant to the possible mutation of TIMP-2, which is a regulator of matrix metalloproteinases (enzymes that are an integral part of extracellular-matrix remodeling and angiogenesis). If studies were to link this given pathway to moyamoya, it might be possible to uncover a mechanism capable of explaining both the primary arteriopathy and the pronounced response to ischemia.

Investigations into the pathogenesis of moyamoya to date suggest that the clinical presentation of affected patients may be the result of disparate underlying genetic and environmental cues. Of particular interest is the genetic link between enzyme regulation and the abnormal levels and activity of related proteins in the aforementioned studies, which may suggest that underly-
ing defects in regulation of specific extracellular proteins have effects on cerebral vessels in susceptible persons, resulting in the moyamoya phenotype when particular environmental triggers, such as radiation, are present.

**Natural History and Prognosis**

The natural history of moyamoya is variable. Disease progression can be slow, with rare, intermittent events, or fulminant, with rapid neurologic decline. However, regardless of the course, moyamoya inevitably progresses in the majority of patients. A 2005 report indicated that the rate of disease progression is high, even among asymptomatic patients, and that medical therapy alone does not halt disease progression. It has been estimated that up to two thirds of patients with moyamoya have symptomatic progression over a 5-year period; the outcome is poor without treatment.

In general, neurologic status at the time of treatment, more than the patient’s age, predicts the long-term outcome. Thus, early diagnosis of moyamoya coupled with the expeditious institution of therapy is of paramount importance.

**Diagnosis**

Moyamoya should be considered — and diagnostic evaluation initiated — in patients, particularly children, presenting with acute neurologic deficits or unexplained symptoms referable to cerebral ischemia. A delay in diagnosis results in a delay in treatment, increasing the risk of permanent disability from stroke. It is critically important to refer patients with moyamoya, or suspected moyamoya, to centers experienced in the care of such patients. Any patient with unexplained symptoms suggestive of cerebral ischemia should be considered as possibly being at risk for moyamoya. Although the differential diagnosis for these symptoms is broad, the presence of moyamoya can be readily confirmed by means of radiographic studies. Radiographic evaluation of a patient suspected of having moyamoya usually requires several studies.

**Computed Tomography**

Computed tomography (CT) in a patient with moyamoya disease may show small areas of hypodensity suggestive of hemorrhage or of a stroke in the cortical watershed zones, basal ganglia, deep white matter, or periventricular regions. However, the CT scan can be normal, particularly in patients presenting solely with T1As. CT angiography can show the intracranial stenoses seen in moyamoya. Thus, CT angiography should be considered when magnetic resonance imaging (MRI) is not readily available and a diagnosis of cerebral occlusive vasculopathy is being considered.

**Magnetic Resonance Imaging**

The widespread availability of MRI and magnetic resonance angiography has led to the increasing use of these methods for primary imaging in patients with symptoms suggestive of moyamoya. An acute infarct is more likely to be detected with the use of diffusion-weighted imaging, whereas a chronic infarct is more likely to be seen with $T_1$- and $T_2$-weighted imaging (Fig. 3A through 3D). Diminished cortical blood flow due to moyamoya can be inferred from fluid-attenuated inversion recovery (FLAIR) sequences showing linear high signals that follow a sulcal pattern, which is called the “ivy sign” (Fig. 3E and 3F). The finding most suggestive of moyamoya on MRI is reduced flow voids in the internal, middle, and anterior cerebral arteries coupled with prominent flow voids through the basal ganglia and thalamus from moyamoya-associated collateral vessels (Fig. 3G and Fig. 3H). These findings are virtually diagnostic of moyamoya.

**Angiography**

Formal angiography should consist of a full five-vessel or six-vessel study that includes both external carotid arteries, both internal carotid arteries, and one or both vertebral arteries, depending on the collateral patterns seen. In a study of 190 patients undergoing diagnostic angiography, complication rates among patients with moyamoya were no higher than those among patients with other forms of cerebrovascular disease. The definitive diagnosis is based on a distinct arteriographic appearance characterized by stenosis of the distal intracranial internal carotid artery, extend-
ing to the proximal anterior and middle arteries (Fig. 1). Disease severity is frequently classified into one of six progressive stages that were originally defined in 1969.\(^2\) Development of an extensive collateral network at the base of the brain along with the classic “puff of smoke” appearance on angiography is seen in the intermediate stages of the Suzuki grading system (Table 2). Imaging of the external carotid arteries is essential to identify any preexisting collateral vessels so that surgery, if performed, will not disrupt them. Aneurysms, as well as the rare arteriovenous malformation known to be associated with certain cases of moyamoya, are also best detected by means of conventional angiography.

**OTHER DIAGNOSTIC TECHNIQUES**

Other diagnostic evaluations that may be useful in evaluating patients with moyamoya include encephalography (EEG) and cerebral blood-flow studies. Specific alterations of EEG recordings, which are usually observed only in children, include posterior or centrotemporal slowing, a hyperventilation-induced diffuse pattern of monophasic slow waves (called “build-up”), and a characteristic “rebuild-up” phenomenon,\(^6,4\) which looks identical to the build-up slow waves seen in patients without moyamoya, but differs in the timing of its presentation. Build-up occurs during hyperventilation, whereas rebuild-up occurs after hyperventilation and indicates a diminished cerebral perfusion reserve.

Techniques such as transcranial Doppler, perfusion CT, xenon-enhanced CT, positron-emission tomography, magnetic resonance perfusion imaging, and single-photon-emission CT with acetazolamide challenge have all been used in the evaluation of patients with moyamoya. These imaging studies may help to quantify blood flow, serve as a baseline before the institution of treatment, and occasionally aid in treatment decisions.

**SCREENING**

There are no data to support indiscriminate screening for moyamoya, and there is little evidence to warrant the screening of first-degree relatives of patients with moyamoya when only a single family member is affected. However, a 2008 article concerning patients with unilateral...
moyamoya showed a decreased stroke burden and better clinical outcome when this specific population underwent imaging at intervals, providing evidence in support of selective screening. Although widespread screening for moyamoya is not yet standard for any specific group, the diagnosis should be considered when patients with certain high-risk disorders such as neurofibromatosis 1, Down’s syndrome, and sickle cell disease are undergoing routine examinations in order to identify symptomatic patients and refer them for imaging.

Table 2. Suzuki Grading System.

<table>
<thead>
<tr>
<th>Grade</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>Narrowing of ICA apex</td>
</tr>
<tr>
<td>II</td>
<td>Initiation of moyamoya collaterals</td>
</tr>
<tr>
<td>III</td>
<td>Progressive ICA stenosis with intensification of moyamoya-associated collaterals</td>
</tr>
<tr>
<td>IV</td>
<td>Development of ECA collaterals</td>
</tr>
<tr>
<td>V</td>
<td>Intensification of ECA collaterals and reduction of moyamoya-associated vessels</td>
</tr>
<tr>
<td>VI</td>
<td>Total occlusion of ICA and disappearance of moyamoya-associated collaterals</td>
</tr>
</tbody>
</table>

*Suzuki and Takaku. ECA denotes external carotid artery, and ICA internal carotid artery.

TREATMENT

No known treatment will reverse the primary disease process, and current treatments are designed to prevent strokes by improving blood flow to the affected cerebral hemisphere. Improvement in cerebral blood flow may provide protection against future strokes, effect a concurrent reduction in moyamoya-associated collaterals, and reduce the frequency of symptoms.

MEDICAL THERAPY

Medical therapy has been used in patients with moyamoya, particularly when surgery has been considered to present a high risk or the patient has had relatively mild disease, but there are few data showing either its short-term or long-term efficacy. A large survey from Japan showed no significant differences in outcome between medically and surgically treated patients with moyamoya, although a more recent review revealed that 38% of 651 patients with moyamoya who were initially treated medically ultimately underwent surgery because of progressive symptoms. Antiplatelet agents have been used to prevent emboli from microthrombi formed at sites of arterial stenosis — a possible cause of ischemic symptoms in patients with moyamoya — and these agents, although not used universally, are used routinely in patients in many operative series. Anticoagulants such as warfarin are rarely used, although there has been some experience with low-molecular-weight heparin. Calcium-channel blockers may be useful in ameliorating intractable headaches or migraines, which are commonly seen in patients with moyamoya, and these agents may be effective in reducing both the frequency and the severity of refractory TIA. Because calcium-channel blockers may cause hypotension, they must be used with caution in this patient population.

SURGERY

The arteriopathy of moyamoya affects the internal carotid artery while sparing the external carotid artery. Surgical treatment of patients with moyamoya typically uses the external carotid artery as a source of new blood flow to the ischemic hemisphere. Two general methods of revascularization are used: direct and indirect. In direct revascularization, a branch of the external carotid artery (usually the superficial temporal artery) is directly anastomosed to a cortical artery. Indirect techniques involve the placement of vascularized tissue supplied by the external carotid artery (e.g., dura, temporalis muscle, or the superficial temporal artery itself) in direct contact with the brain, leading to an ingrowth of new blood vessels to the underlying cerebral cortex.

Historically, direct procedures have been used in adults for whom an immediate increase of blood flow to the ischemic brain is a major benefit. Augmentation of cerebral blood flow usually does not occur for several weeks with indirect techniques. However, direct bypass is often technically difficult to perform in children because of the small size of both donor and recipient vessels, making indirect techniques appealing. Nonetheless, direct operations have been successful in some children, and indirect procedures have been successful in some adults. There is considerable debate about the relative merits and shortcomings of the two approaches; in fact, some centers advocate a combination of direct and indirect approaches.
Indirect revascularization procedures include encephaloduroarteriosynangiosis, encephalomyoarteriosynangiosis, pial synangiosis (Fig. 4), and the drilling of burr holes without vessel synangiosis.\textsuperscript{12,75-80} A review of 143 patients treated with pial synangiosis showed marked reductions in the frequency of stroke after surgery; 67\% of the patients had strokes before treatment, whereas 7.7\% had strokes in the perioperative period, and only 3.2\% had strokes after at least 1 year of follow-up. Among patients who had a minimum of 5 years of follow-up, the long-term rate of stroke was 4\% (2 of 46 patients).\textsuperscript{12}

Increasingly, surgical revascularization is gaining acceptance as a primary treatment for moyamoya, given the contrast between the poor response to medical therapy and the documented success of surgery.\textsuperscript{58} Two large studies with long-term follow-up showed a good safety profile for surgical treatment. The risk of stroke is highest within the first 30 days after surgery (approximately 4\% per hemisphere); after the first month, the risk decreases considerably. Patients reportedly have a 96\% probability of remaining stroke-free over the subsequent 5 years.\textsuperscript{12,55} A meta-analysis concluded that 1003 of 1156 patients (87\%) derived symptomatic benefit from surgical revascularization, with indirect, direct, and combined techniques showing equal effectiveness.\textsuperscript{58}

Patients with moyamoya have an additional risk of ischemic events during the perioperative period. Potential complications of surgery for moyamoya include stroke, infection, and intracranial hemorrhage. As previously noted, crying and hyperventilation can lower the partial pressure of carbon dioxide and induce ischemia due to cerebral vasoconstriction. Effective pain control, including the use of perioperative sedation, painless wound-dressing techniques, and closure of the wound with absorbable sutures to prevent the pain of suture removal may reduce the likelihood of postoperative stroke and shorten the duration of hospitalization.\textsuperscript{81} During surgery, it is important to avoid hypotension, hypovolemia, hyperthermia, and both hypocarbia and hypercarbia.\textsuperscript{12,82} Postoperatively, patients should be given intravenous fluids at 1.25 to 1.50 times the normal maintenance rate for 48 to 72 hours.\textsuperscript{81}

**TREATMENT OF ACUTE SYMPTOMS**

When patients present with cerebral ischemia, oxygenation and the rapid institution of measures to increase cerebral blood flow may reduce the likelihood that a TIA will progress to a completed stroke. Initial treatment steps are similar to perioperative management and should include intravenous hydration with isotonic fluids (usually at a daily dose of 1.25 to 1.50 times the normal maintenance rate), avoidance of hypotension, and administration of supplemental oxygen.\textsuperscript{12,81,83} Hyperventilation is to be avoided. Serum electrolyte and glucose levels should be normalized. Seizure activity, if present, should be treated with appropriate pharmacologic agents.

Imaging can be performed on an emergency basis to ascertain whether a hemorrhage has occurred. Although patients are often evaluated initially with the use of CT, which will readily detect hemorrhage, MRI with diffusion-weighted images will confirm the presence of a completed stroke. In the absence of hemorrhage, antiplatelet agents
can be used, as noted above, to lessen the likelihood that microthrombi will form at sites of arterial stenosis. Aspirin is used at many institutions (at a daily dose of 325 mg for adults and 81 mg [or less] for preteen children), and treatment is instituted even when surgical revascularization is planned.

CONCLUSIONS

Moyamoya is an increasingly recognized cause of stroke in both children and adults. Patients with certain conditions such as Down’s syndrome and sickle cell disease may be particularly at risk for moyamoya. Characteristic radiographic findings confirm the diagnosis, and recognition of the disease early in its course, with prompt institution of therapy, is critical in order to achieve the best outcome in patients. Revascularization surgery appears to be effective in preventing stroke in patients with moyamoya.

No potential conflict of interest relevant to this article was reported.

REFERENCES

27. Lim M, Cheshier S, Steinberg GK.
70. Dauser RC, Tuite GF, McCluggage

Copyright © 2009 Massachusetts Medical Society.